Fig. 1From: TNFα inhibitors as targets for protective therapies in MSA: a viewpointTNFα in MSA pathogenesis. Misfolded αS leads to microglial activation and subsequent microglial release of pro-inflammatory cytokines. High levels of TNFα in vulnerable brain areas in MSA contribute to αS aggregation and establish a pro-apoptotic environment in chronic diseaseBack to article page